Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis

Key Points

• Adjunctive GLP-1 receptor agonists and SGLT2 inhibitors provide modest clinical improvements.
• Increased risk of diabetic ketoacidosis is noted with SGLT2-based therapies.
• This systematic review and meta-analysis assess safety and efficacy of these interventions.
• Larger long-term trials are necessary to optimize the use of these therapies.